THERAPY DOSSIER · th-03d1f4102574

JP4-039 (mitochondrion-targeted GS-nitroxide, derivative of 4-amino-Tempo)

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 29391546 ↗2018Reported benefit

The GS-nitroxide JP4-039 improves intestinal barrier and stem cell recovery in irradiated mice.

MouseRadiationC57BL/6NTac (C57BL/6 for the 10 Gy bone marrow transplantation experiments)Femalen = N = 3 mice per group for tissue, RNA and histology endpoint…Intravenous20 mg/kg, approximately 400 micrograms per mouse24 hours after total body irradiation

Model: Total body irradiation at 9.25 Gy or 9.5 Gy delivered in a caesium irradiator at 76 cGy/min; 10 Gy or 15 Gy total body or abdominal irradiation used in additional experiments

A single intravenous dose of JP4-039 given 24 hours after 9.25 Gy or 9.5 Gy total body irradiation raised 35 day survival from 25 per cent and 10 per cent respectively to 75 per cent. Treatment halved goblet cell loss, restored enteroendocrine cell numbers by day 12, recovered tight junction transc…

Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

Loading the evidence…